Experts Matter. Find Yours.
Connect for media, speaking, professional opportunities & more.
UConn Expert on the "FDA's Big Gamble" with Controversial Alzheimer's Drug
The Food and Drug Administration's accelerated approval of the drug aducanumab for the treatment of Alzheimer's disease is mired in controversy -- three scientists have resigned from the independent committee that advised the agency on the monthly infusion treatment priced at $56,000 per year. C. Michael White, distinguished professor and head of the Department of Pharmacy Practice at the University of Connecticut, explains the situation surrounding the drug's approval this week in an essay published by The Conversation: Over 6 million Americans now have Alzheimer’s disease, and deaths from Alzheimer’s have risen over 145% over the past 20 years. Alzheimer’s disease not only robs individuals of their autonomy but also places a huge burden on family members and the U.S. economy: $355 billion is spent annually on caring for people with Alzheimer’s. Current FDA-approved treatments are only modestly effective at controlling disease symptoms, and none target a possible underlying cause. The accelerated approval pathway allows patients with early-stage Alzheimer’s to access aducanumab while a larger and more definitive clinical trial is conducted. Biogen says it hopes to have the clinical trial completed by 2030. If the study does not find reductions in the hard clinical endpoints, the drug will be withdrawn. If aducanumab is ultimately found to be effective, many patients with early-stage Alzheimer’s will reap the benefits in reductions in hospitalizations, doctor visits, nursing home costs and societal burden. If aducanumab is found to be ineffective, however, Medicare, insurers and patients will have spent tens of millions of dollars on a drug that not only did not work but also exposed patients to adverse events, including the risk of bleeding in the brain. June 10 - The Conversation Dr. C. Michael White is an expert in the areas of comparative effectiveness and preventing adverse events from drugs, devices, dietary supplements, and illicit substances. If you are a journalist looking to cover this topic, then let us help. Dr. White is available to speak with media -- click on his icon now to arrange an interview today.
A leading London based architectural metalwork company, specialising in the design, fabrication and installation of bespoke metal products has entered into a Knowledge Transfer Partnership (KTP) with Aston University, with the aim of developing antimicrobial coatings as a way to reduce infection in high risk environments. The Aston University research team will work with John Desmond Limited to develop high end metallic products that can be used where there is a high risk of the spread of bacteria. The antimicrobial coating will be developed for use in communal areas on products such as handrails, balustrades, push plates, door handles and faceplates, – all of which are common in high traffic areas such as hospitals, doctors surgeries, dental practices, schools and transportation hubs. A Knowledge Transfer Partnership (KTP) is a three-way partnership between a business, an academic partner and a graduate, called a KTP Associate. The UK-wide programme helps businesses to improve their competitiveness and productivity through the better use of knowledge, technology and skills. Aston University is the leading KTP provider within the Midlands. Microbiologists from Aston University’s College of Health and Life Sciences and materials scientists from its College of Engineering and Physical Science will establish the effectiveness of the antimicrobial coatings against a panel of bacteria under a range of conditions to further optimise the surface performance. The team will support John Desmond Ltd to establish an in-house microbiology laboratory to enable extensive testing of the developed coatings which will be carried out under lab conditions. Information from the lab tests will provide supporting evidence to prospective clients of the antimicrobial coating’s efficacy, expected lifespan and performance under varying conditions. Ian Desmond, owner of John Desmond Ltd, said: “We are very excited to be working with Aston University on this ground-breaking project to develop industrial coatings capable of reducing the spread of infection within public spaces. “We are confident that with the expert knowledge and experience that the Aston University team brings to this collaboration, we will succeed in formulating a potent cost-effective means to protect all of us from the threat of micro-organisms, and their impact on the environment in which we live and work.” The Aston University academic team consists of Dr Tony Worthington, associate professor in clinical microbiology and infectious disease; Professor Anthony Hilton, and executive dean of the College of Health and Life Sciences, and Dr Richard Martin from the Aston Institute of Materials Research in the College of Engineering and Physical Science. Professor Anthony Hilton said: “I’m delighted to be able to work on this exciting project with John Desmond Ltd, bringing together a multi-disciplinary team of scientists and engineers from across Aston University to work with an industry partner. “Knowledge exchange between academia and industry is a core element of Aston University’s strategy and it is exciting to be part of a team developing a product which has the potential to have real impact in preventing and controlling infection.” Dr Richard Martin, Aston Institute of Materials Research, said: “Over the past year, we have all become aware of just how important it is to limit the spread of microorganisms. This project is an exciting opportunity to develop new antimicrobial coatings that will significantly reduce the transmission of microorganisms from touchpoint surfaces such as door handles and handrails." The research team have found that claims for the effectiveness of the anti-microbial properties of products already on the market are not always backed with scientifically rigorous evidence. As a result of this, these products have not been able to penetrate markets such as healthcare, where generic claims are not sufficient for buyers to change suppliers. This KTP will establish a body of testing and efficacy data which will support the application and use of antimicrobial coatings in a range of settings where control of bacteria on environmental surfaces is critical for infection prevention and control. You can visit our website for more information about The College of Health and Life Sciences and The College of Engineering and Physical Science at Aston University.
Maple Report - May 2021 Edition
May 2021 Welcome to our second edition of The Maple Report. This quarterly newsletter is designed to keep Canadian technology executives updated on the latest trends, market research, events and valuable resources from IDC Canada's expert analysts. In this edition, we want to show you how IDC can help Canadian executives like yourself make important technology decisions. We also want to invite you to our upcoming events and give you a sample of some of our thought leadership through our IDC blog. We hope you find these insights practical to help propel your business into a more resilient digital enterprise. Trust IDC to be your research partner in 2021. We welcome your thoughts about this newsletter. Please send them to askIDC@idccanada.com. HOW CAN IDC HELP YOU? IDC PeerScapes – Helping You Find Technology Best Practices An IDC PeerScape minimizes your missteps by identifying peer business practices worthy of emulating or avoiding, increasing the likelihood of positive impacts from a technology initiative. To assist your organization finding technology best practices, IDC publishes dozens of IDC PeerScape reports. Similar to IDC MarketScapes that we explored in the last edition of The Maple Report, IDC PeerScapes sit on the Engage part of our IDC DecisionScape framework , and include reports to help you launch, evaluate and optimize new technology initiatives. The report outlines key challenges your peers encountered when implementing a specific technology initiative, as well as key insights your peers learned along the way. IDC PeerScapes help you to increase the likelihood of a tech initiative’s success by giving you insight into best practices (and practices to avoid) through specific use case examples implemented by your peers who have already led a similar technology initiative. These documents can help your organization recreate successful implementations of technology and help you mitigate risk. To help you understand the value of these reports, we have included here our IDC PeerScape: Practices for Including Cloud Services into Outsourcing Contracts in Canada report. In it, you'll find Best practices from three areas of cloud adoption are discussed in the document: security, cost management, and skills gap. Companies created security checklists to mitigate security risks and retain control of security when working with external vendors. They also filled the skills gap and minimized cost unpredictability by collaborating with their outsourcing service providers. VIRTUAL EVENTS FOR IT EXECUTIVES IDC Fireside Chat | Content Cloud as a Critical Component of Virtual Work May 19, 2021 | 2:00 pm ET Does your organization have a holistic view of your customers when they contact you for assistance? Are your security protocols on your content systems up to snuff with your virtual workforce? Is your content customized for the different employee roles? If any of these content challenges sound familiar to your organization, then you need to attend this webinar to provide a seamless content experience for your customers and your employees. On our next webinar for Canadian technology executives on May 19th at 2pm ET, we'll hear how ATB Financial's Barry Hensch conquered multiple content management challenges to provide seamless experiences in its virtual workplace during a fireside chat with IDC's Megha Kumar. Walk away with a better understanding of what Cloud Content Management entails, why it's important to manage your content effectively and how you can leverage it to prosper in the digital future. Confirmed Speakers: Megha Kumar: Director, Software & Cloud Services, IDC Canada Barry Hensch: SVP & Head of Technology Enablement, ATB Financial Varun Parmar: SVP & Chief Product Officer, Box IDC CIO Panel Series | Accelerate & Simplify Your Canadian Digital Transformation Journey June 16, 2021 | 2:00pm ET Our IDC Canada research indicates that many Canadian organizations are not where they need to be yet to thrive in the digital economy. If you think your organization could benefit from simplifying and accelerating your digital transformation efforts, then you need to attend this upcoming webinar on June 16 at 2pm ET. Join this virtual webinar to understand where Canadian organizations are on their respective digital transformation journeys, what types of projects were accelerated as a result of the pandemic and what impact it had on Canadian industries. Then hear from our all-Canadian CIO panel on how they've stickhandled the impact of the pandemic at their organizations to set themselves up for future success in the digital economy. Learn what you need from your peers to get your organization moving in the right direction. Confirmed Speakers: Tony Olvet: Group VP, Research, IDC Canada Nigel Wallis: Research VP, IoT & Industries, IDC Canada Catherine Chick: SVP, IT, Canada Goose Pamela Pelletier: Canada Country Manager, Dell Technologies IDC THOUGHT LEADERSHIP HIGHLIGHTS DID YOU KNOW? You Can Get Actionable Research, KPIs, Benchmarks & Best Practices with IDC IDC Canada's IT Executive Programs (IEP) make it easy to access the relevant technology research and advice you need to make data-driven decisions as you lead your organization into the digital future. Get in touch today to learn more or visit our IT Executive Portal to learn more. IT EXECUTIVE RESOURCES Set Your Future IT Roadmap with IDC IT leaders need to rethink what is critical and evaluate where the organization stands as they manage complex changes. For strategies on transforming your organization's IT, read the new eBook from IDC: Future IT: Operating System of the Future Enterprise.
Bridge-Building as a Career Path
Yusuhara Wooden Bridge Museum / Kengo Kuma & Associates. © Takumi Ota For my entire life I’ve imagined myself as a bridge between the U.S. and Japan. I grew up in Japan from ages one to eighteen — my parents are Southern Baptist missionaries who have lived in our heartland now for over 40 years. As an American growing up in Hokkaido, I often found myself in the position of explaining to Japanese why Americans do certain things and act certain ways, and then trying to tell Americans why Japanese or people outside of the U.S. saw the country in a particular way. This dialogue became an extension of who I am. Of course, like many children growing up, I wanted to be like my dad, who is a gifted pastor and long-term missionary. But, along the way, I realized that the role of a missionary is actually very much like that of being an ambassador or bridge-builder who represents their country, alliances, and traditions. As reinforced recently by Prime Minister Suga’s visit to the White House, the first of any international visitor for the Biden administration, the alliance with Japan is our single most strategic international relationship. Walter Russel Meade laid this out eloquently in the Wall Street Journal, “For the foreseeable future, the U.S.-Japan alliance is likely to remain the cornerstone of American foreign policy. Building the social and cultural ties that can support that relationship is an urgent task for both countries.” In my lifetime, and perhaps never before, has there been a moment like the present where the U.S. and Japan are mutually reliant to such a degree. Therefore, my personal commitment to being a bridge-builder, and our mission at Japan Society, have never been more critical. Finding my path After college I went to Turkey as a Fulbright Scholar, where I worked with the State Department through the Ambassador’s Office and the Embassy, enriching my understanding of foreign diplomacy. As I explored my interests in other parts of the world, I didn’t intend to pursue a career in U.S.-Japan relations. However, all that changed on March 11, 2011, when the Great East Japan Earthquake, tsunami, and nuclear disaster devastated the Tohoku region of northeastern Japan. At that moment, I felt a deep personal mission to help bring people from around the world together and realized that I was uniquely situated to build bridges with Japan. I had the opportunity to serve three different times in the State Department along with the Defense Department and on various Commerce Department advisory boards as I completed my academic degrees culminating with a PhD from Princeton. My time in academia and government service taught me the important skill of storytelling. When I left the State Department, I joined the strategic communications company APCO Worldwide, where I helped establish their Japan office and became immersed in Japanese public relations. Next, I had the privilege of running the USA Pavilion at the World Expo in Kazakhstan in 2017, telling America’s story from the ground up. That led me to Eurasia Group, the foremost geopolitical risk consultancy group, where I led the largest geopolitical risk summit in Japan, the GZero Summit, taking my academic, government, and public relations experience and putting it into a practical context. Embracing my ikigai Today I’m the President and CEO of Japan Society, working to take the Society’s mission into its second century, to be the deep connection, or kizuna, that brings the United States and Japan together through its peoples, culture, businesses, and societies. One of the greatest things that I see these days is concepts from Japan that have been adapted into the English lexicon — like ikigai, the idea of life’s purpose, which has become a catchphrase in our pandemic world’s search for meaning. Ikigai resonates deeply with me, because it is about finding your reason for being, your passion and calling. For me, this means being dedicated to promoting global understanding and helping make the world a better place. I don’t think I would have told you two years ago that I would be the President and CEO of Japan Society. It is an opportunity that caught me by surprise in some ways. But in other ways, now that I am here, it feels like the most natural job I’ve ever done, and I cannot think of a better place I would rather be or a better way to live out my ikigai. At Japan Society’s founding luncheon on May 19, 1907, the guest of honor, General Baron Kuroki “wished the new organization a long and successful health.” As The New York Times reported, “The object of the new organization will be the promotion of friendly relations between the United States and Japan.” Now in its second century, our work of bridge-building continues today. Joshua Walker (@drjwalk) is president and CEO of Japan Society. Follow @japansociety. The views expressed in this article are the writer’s own.
Thousands of men to trial prostate cancer home testing kit
Thousands of men worldwide are to receive a home test kit for prostate cancer – thanks to pioneering research from the University of East Anglia and the Norfolk and Norwich University Hospital (NNUH). The research team are trialling a new home-testing ‘Prostate Screening Box’ to collect men’s urine samples at-home. The urine samples will be used to analyse the health of the prostate in 2,000 men in the UK, Europe and Canada. This simple urine test is intended to diagnose aggressive prostate cancer and in a pilot study predicted which patients required treatment up to five years earlier than standard clinical methods. Lead researcher Dr Jeremy Clark from the University of East Anglia 'unboxes' the new home testing kit live on Sky News. The Prostate Screening Box has been developed in collaboration with REAL Digital International Limited to create a kit that fits through a standard letterbox. It means that men can provide a urine sample in the comfort of their own home, instead of going into a clinic or having to undergo an uncomfortable rectal examination. The research team hope that it could revolutionise diagnosis of the disease. Lead researcher Dr Jeremy Clark, from UEA’s Norwich Medical School, said: “Prostate cancer is the most common cancer in men in the UK. However it usually develops slowly and the majority of cancers will not require treatment in a man’s lifetime. It is not a simple matter to predict which tumours will become aggressive, making it hard to decide on treatment for many men. “The most commonly used tests for prostate cancer include blood tests, a physical examination known as a digital rectal examination (DRE), an MRI scan or a biopsy. “We have developed the PUR (Prostate Urine Risk) test, which looks at gene expression in urine samples and provides vital information about whether a cancer is aggressive or ‘low risk’. “The Prostate Screening Box part sounds like quite a small innovation, but it means that in future the monitoring of cancer in men could be so much less stressful for them and reduce the number of expensive trips to the hospital. “The prostate lies just below the bladder. It constantly produces secretions which naturally flow into the urethra - the tube through which urine passes from the bladder. The prostatic secretions carry cells and molecules from all over the prostate which are flushed out of the body on urination. We collect these and examine them. It’s a way of sampling the whole prostate in one go. “As the prostate is constantly secreting, the levels of biomarkers in the urethra will build up with time. Collecting from the first wee of the day means that overnight secretions can be collected which makes the analysis more sensitive.” The team have previously trialled the kit with a small group of participants, but in the next phase of the research study are rolling it out to thousands. Men taking part in the trial will receive a home urine-sampling kit and will be asked to provide two urine samples – one to be taken first thing in the morning and the second an hour later. The samples will then be sent back to the lab for analysis. Dr Clark said: “Feedback from early participants showed that the at-home collection was much preferred over sample collection in a hospital. “We hope that using our Prostate Screening Box could in future revolutionise how those on ‘active surveillance’ are monitored for disease progression, with men only having to visit the clinic after a positive urine result. “This is in contrast to the current situation where men are recalled to the clinic every six to 12 months for a range of tests including DRE, PSA tests, painful and expensive biopsies and MRI. We are working to develop the test to help patients in three years’ time. “A negative test could enable men to only be retested every two to three years, relieving stress to the patient and reducing hospital workload,” he added. Robert Mills, Consultant Clinical Director in Urology at NNUH, said: “This simple, non-invasive urine test has the potential to significantly change how we diagnose and manage early prostate cancer for the benefit of patients and health care systems. It may enable us to avoid unnecessary diagnosis of low risk disease as well as managing patients more appropriately with surveillance for those with low risk of progression and early curative treatment for those at high risk of progression.” Paul Villanti, executive director of programs at Movember, said: “The PUR test has great potential to transform the way prostate cancer is managed. Not only can it accurately predict when a man’s disease will become aggressive and require treatment, but it has the added advantage of allowing men to complete it at home. “We are proud to have supported the development of the PUR test from its early stages as part of our Global Action Plan on Biomarkers, through to this trial involving thousands of men across the world. “Through our Global Action Plan on active surveillance, we have been able to identify hundreds of men from the UK, Germany, Italy and Canada who are suitable to take part in this trial. “We hope it will speed up the trial’s progress and get this test included as part of clinical care for men as quickly as possible.” The research has been funded by a Movember and Prostate Cancer UK Innovation award, the Masonic Charitable Foundation, the Bob Champion Cancer Trust, the King family, the Andy Ripley Memorial Fund, the Hargrave Foundation, Norfolk Freemasons and the Tesco Centenary Grant.
Social Work is Advancing Addiction Science Research
Tens of thousands of Americans die from drug use and addiction every year, with overdoses killing over 63,000 people in America in 2016, according to the National Institute on Drug Abuse. Add in deaths linked to alcohol overuse and tobacco, and the number climbs above half a million Americans. The collective work of several researchers at the USC Suzanne Dworak-Peck School of Social Work, in collaboration with other USC faculty and outside organizations, is advancing knowledge of substance use disorders. Social work has become a hub where researchers and practitioners drive understanding and improve treatment for this disease that impacts millions of families each year. “Either as a cause or consequence, addiction relates to every problem we deal with in social work,” said John Clapp, professor and associate dean for research and faculty development at the USC Suzanne Dworak-Peck School of Social Work. Addiction’s complexity The social work field is uniquely poised to help effect change because of its holistic approach to individual well-being and the public good. According to Clapp, substance use disorder problems are inherently ecological, impacting and being impacted by individuals, families, peers, neighborhoods, communities and public policy in complex and dynamic ways. Untangling those causes and effects and interdependencies is one part of the solution. The other part is understanding that simple solutions may stay out of reach. “We will not find a one-size-fits-all answer,” said Clapp. Looking at addiction as a genetic, psychological or sociological issue only shows one piece of the overall cause. A comprehensive approach is essential, he said, especially when statistics from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) show alcohol use disorders alone as the third leading cause of preventable death in the world. A hub for addiction science The need for a transdisciplinary response to this worldwide crisis was behind the 2018 creation of the USC Institute on Addiction Science (IAS), a joint venture between social work and the Keck School of Medicine of USC, with membership from 10 different schools, colleges and hospitals. Its vision is to strengthen the discipline of addiction science and improve the lives of those touched by the disease. Clapp is co-director of the institute and one of its founding architects. IAS is quickly becoming the foremost place for a broad effort focused on addiction that brings together researchers from the fields of public health, social work, law, public policy, mathematicians, computer engineers and others in recognition of the promise of new approaches to longstanding problems. The USC Suzanne Dworak-Peck School of Social Work has eight faculty making substantial contributions to the prevention of addiction-related disorders as members of the IAS: Professor Avalardo Valdez, associate professors Julie Cederbaum and Alice Cepeda, and assistant professors Jordan Davis, Shannon Dunn, Jungeun Olivia Lee, Danielle Madden, and Hans Oh. “Social work brings one of the broadest perspectives on the underpinnings and solutions to the addiction crisis,” said Adam Leventhal, director of IAS and professor of preventive medicine and psychology at Keck. “By approaching addiction as a health condition and a social justice issue, social work brings to the table the opportunity for high-impact, multi-modal intervention and social policy approaches, which are needed to address the addiction epidemic.” A holistic approach Social work faculty are raising the bar in addiction science research, developing new and novel approaches to improving outcomes for those affected by addiction. In a study recently published in Addiction, a multidisciplinary team lead by Davis and Clapp found gender differences in the risk factors for relapse following treatment for opioid use disorder. The study was the first in this field to use machine learning techniques to process large data sets and identify risk factors for relapse, said Davis, who also serves as associate director of the USC Center for Artificial Intelligence in Society (CAIS). The findings may result in more personalized treatment for opioid use disorder with lasting results. This dovetails with additional research Davis is conducting with computer science engineers at CAIS to collect and input neighborhood and census data into their models in an effort to better understand how these macro variables affect relapse. “We are finding that data points such as crime statistics, population density and concentrated poverty tend to be some of the most important predictors of relapse, over and above individual-level predictors such as impulsivity, motivation or gender,” Davis said. These findings echo Clapp’s description of addiction as ecological and point to the need for holistic solutions. “These machine learning techniques are helping us gain an apparent picture of what the most important factors are surrounding someone’s recovery,” Davis said. “Environment matters greatly.” Davis is also collaborating closely with Eric Pedersen, associate professor at Keck School of Medicine at USC, on several research efforts examining substance use among veterans. Most recently, they have assembled a survey group of approximately 1,200 veterans whom they survey quarterly about their well-being. A recently conducted survey of the group found that veterans with PTSD prior to the COVID-19 pandemic were now managing their symptoms with more frequent alcohol and cannabis use. Another joint research endeavor between the two is examining the use of mindfulness smart phone apps to help reduce substance use in Operation Enduring Freedom/Operation Iraqi Freedom veterans with PTSD and alcohol use disorder. Where well-being and inequalities intersect Jungeun Olivia Lee also seeks to decode the network of relationships between socioeconomic status, adverse childhood experiences and drug use. Her experience as a social work practitioner working directly with clients drives her motivation to demonstrate to policymakers what she sees as a linkage between unemployment, economic stress and substance use disorders. She is lead author on a paper published in Nicotine & Tobacco Research that found unemployment may advance nicotine addiction among young adults, rather than the idea that nicotine addiction may lead to unemployment. Lee’s research interests lie at the intersection of substance use and co-occurring mental health, social inequalities (such as poverty and low socioeconomic status), and adverse childhood experiences. She is interested in combining these three areas of inquiry to explore their influence on addictive behavior that can persist over generations of at-risk families, such as adolescent mothers and their children. Her memories of working directly with clients struggling with the impact of addiction remain clear in her mind. When Lee hears policymakers and others suggest that individual willpower will solve substance use disorder problems, she has a straightforward response: “People are not born with addiction.” In her view, many factors contribute to the triggered distress, including socioeconomic status and adverse childhood experiences. Lee is exploring an idea with other IAS researchers to investigate the relationship between financial strain and employment uncertainty and addiction. “Individual circumstances, such as losing a job, certainly influence substance use, but policy-level decisions, such as the generosity of unemployment insurance, can mitigate the impact,” she said. Transdisciplinary collaboration with social scientists, psychologists and medical researchers at IAS and across the USC campus enriches and amplifies her work. “We are breaking down discipline-specific silos and bringing new and valuable perspectives to this work,” she said. “The synergy is both useful and inspiring.” Looking ahead Researchers also hope to spark interest in the field among the next generation. A new minor for undergraduate students in addiction science was introduced at USC in Fall 2020. The minor is an interdisciplinary collaboration of the Keck School of Medicine, the USC Suzanne Dworak-Peck School of Social Work, the USC School of Pharmacy and the USC Dornsife College of Letters, Arts, and Sciences. It is designed to provide students with a transdisciplinary approach to understanding and treatment of the broad spectrum of addiction-related problems. The goal of addiction science research and education is to improve the long-term effect of addiction treatment and save lives. As society’s understanding of the cause of addiction grows, researchers like those in the school of social work and the IAS strive to bridge the gap between science, practice and policy to positively impact outcomes for those affected by addiction.
New prostate cancer urine test shows how aggressive disease is and could reduce invasive biopsies
Researchers from the University of East Anglia have developed a new urine test for prostate cancer which also shows how aggressive the disease is. A new study shows how an experimental new test called ‘ExoGrail’ has the potential to revolutionise how patients with suspected prostate cancer are risk-assessed prior to an invasive biopsy. The research team say their new test could reduce the number of unnecessary prostate cancer biopsies by 35 per cent. Prostate cancer is the most common cancer in men in the UK. It usually develops slowly and the majority of cancers will not require treatment in a man’s lifetime. The most commonly used tests for prostate cancer include blood tests, a physical examination known as a digital rectal examination (DRE), an MRI scan or an invasive biopsy. However, doctors struggle to predict which tumours will become aggressive, making it hard to decide on treatment for many men. Lead researcher Dr Dan Brewer, from UEA’s Norwich Medical School, said: “While prostate cancer is responsible for a large proportion of all male cancer deaths, it is more commonly a disease men die with rather than from. “Therefore, there is a desperate need for improvements in diagnosing and predicting outcomes for prostate cancer patients to minimise over-diagnosis and overtreatment whilst appropriately treating men with aggressive disease, especially if this can be done without taking an invasive biopsy. “Invasive biopsies come at considerable economic, psychological and societal cost to patients and healthcare systems alike.” The research team developed the new ExoGrail urine test by combining two biomarker sources - measurements of a protein-marker called EN2 and the levels of gene expression of 10 genes related to prostate cancer risk. It builds on previously developed tests called PUR and ExoMeth. They tested it using urine samples from 207 patients who had been undergone a biopsy for prostate cancer at the Norfolk and Norwich University Hospital (NNUH). When the urine results were compared to biopsy results, the study showed that the test had successfully shown which patients had prostate cancer and which did not. The ExoGrail test also provided risk scores for patients and highlighted those for which an invasive biopsy would have been beneficial. The findings show that using information from multiple, non-invasive biomarker sources has the potential to greatly improve how patients with suspected prostate cancer are risk-assessed prior to an invasive biopsy. Dr Brewer said: “Our new urine test not only shows whether a patient has prostate cancer, but it importantly shows how aggressive the disease is. This allows patients and doctors to select the correct treatment. And it has the potential to reduce the number of unnecessary biopsies by 35 per cent.” The research team was led by Dr Shea Connell, Prof Colin Cooper, Dr Daniel Brewer and Dr Jeremy Clark, all from UEA’s Norwich Medical School, in collaboration with the Norfolk and Norwich University Hospital, the University of Surrey, the University of Bradford, The Earlham Institute, and The Movember GAP1 Urine Biomarker Consortium. The urine biomarker research was funded by the Movember GAP1 Urine Biomarker project, Prostate Cancer UK, The Masonic Charitable Foundation, The Bob Champion Cancer Trust, the King family, The Andy Ripley Memorial Fund, the Hargrave Foundation, Norfolk Freemasons and the Tesco Centenary Grant. Paul Villanti, executive director of programmes at Movember, said: “We are proud to have supported the development of the ExoGrail urine test as part of our Global Action Plan Urine Biomarker project. “Having non-invasive tests which can accurately show how aggressive a man’s prostate cancer is not only reduces the number of men having to undergo painful biopsies, but also ensures that the right course of treatment for the patient is selected more quickly.” ‘Integration of Urinary EN2 Protein & Cell-Free RNA Data in the Development of a Multivariable Risk Model for the Detection of Prostate Cancer Prior to Biopsy’ is published in the journal Cancers on Tuesday, April 27, 2021.
Novel coronavirus discovered in British bats
A coronavirus related to the virus that causes Covid-19 in humans has been found in UK horseshoe bats – according to new collaborative research from the University of East Anglia, ZSL (Zoological Society of London), and Public Health England (PHE). However, there is no evidence that this novel virus has been transmitted to humans, or that it could in future, unless it mutates. UEA researchers collected faecal samples from more than 50 lesser horseshoe bats in Somerset, Gloucestershire and Wales and sent them for viral analysis at Public Health England. Genome sequencing found a novel coronavirus in one of the bat samples, which the team have named ‘RhGB01’. Due to the rapid response nature of this research, it has not yet been peer reviewed. It is the first time that a sarbecovirus (SARS-related coronavirus) has been found in a lesser horseshoe bat and the first to be discovered in the UK. The research team say that these bats will almost certainly have harboured the virus for a very long time. And it has been found now, because this is the first time that they have been tested. Importantly, this novel virus is unlikely to pose a direct risk to humans, unless it mutates. A mutation could happen if a human infected with Covid-19 passes it to an infected bat, so anyone coming into contact with bats or their droppings, for example those engaged in caving or bat protection, should wear appropriate PPE. Prof Diana Bell, an expert in emerging zoonotic diseases from UEA’s School of Biological Sciences, said: “Horseshoe bats are found across Europe, Africa, Asia and Australia and the bats we tested lie at the western extreme of their range. “Similar viruses have been found in other horseshoe bat species in China, South East Asia and Eastern Europe. “Our research extends both the geographic and species ranges of these types of viruses and suggests their more widespread presence across more than 90 species of horseshoe bats. “These bats will almost certainly have harboured this virus for a very long time – probably many thousands of years. We didn’t know about it before because this is the first time that such tests have been carried out in UK bats. “We already know that there are different coronaviruses in many other mammal species too,” she said. “This is a case of ‘seek and you will find’. “Research into the origins of SARS-CoV-2, the virus that causes Covid-19 in humans, has focussed on horseshoe bats - but there are some 1,400 other bat species and they comprise 20 per cent of known mammals. “Our findings highlight the need for robust genotype testing for these types of viruses in bat populations around the world. And it raises an important question about what other animals carry these types of viruses.” Prof Andrew Cunningham, from the Zoological Society of London, said: “Our findings highlight that the natural distribution of sarbecoviruses and opportunities for recombination through intermediate host co-infection have been underestimated. “This UK virus is not a threat to humans because the receptor binding domain (RBD) – the part of the virus that attaches to host cells to infect them - is not compatible with being able to infect human cells. “But the problem is that any bat harbouring a SARS-like coronavirus can act as a melting pot for virus mutation. So if a bat with the RhGB01 infection we found were to become infected with SARS-CoV-2, there is a risk that these viruses would hybridise and a new virus emerge with the RBD of SARS-CoV-2, and so be able to infect people. “Preventing transmission of SARS-CoV-2 from humans to bats, and hence reducing opportunities for virus mutation, is critical with the current global mass vaccination campaign against this virus.” Prof Bell added: “The main risks would be for example a bat rehabilitator looking after a rescued animal and infecting it with SARS-CoV2 - which would provide an opportunity for genetic recombination if it is already carrying another sarbecovirus. “Anyone coming into contact with bats or their droppings, such as bat rescuers or cavers, should wear appropriate PPE – in order to reduce the risk of a mutation occurring. “We need to apply stringent regulations globally for anyone handling bats and other wild animals,” she added. The new virus falls within the subgroup of coronaviruses called sarbecoviruses which contains both SARS-CoV-2 (responsible for the current pandemic) and SARS-CoV (responsible for the initial 2003 SARS outbreak in humans). Further analysis compared the virus with those found in other horseshoe bat species in China, South East Asia and Europe and showed that its closest relative was discovered in a Blasius’s bat from Bulgaria in 2008. Ivana’s story The UK discovery was made by undergraduate ecology student Ivana Murphy, from UEA’s School of Biological Sciences, who collected bat droppings as part of her final year research dissertation. Jack Crook conducted the genetic analyses in partnership with other researchers at PHE. A total of 53 bats were captured, and their faeces collected in sterile bags. The research was conducted under strict Health and Safety protocols. Full PPE was worn and Ivana was regularly tested for Covid-19 to avoid any chance of cross contamination. The bats were released immediately after their droppings had been collected. Ivana said: “I am very fortunate to be surrounded by so many experts in their fields, which has allowed me access to resources that many undergraduates wouldn’t have. I feel extremely lucky to have been able to conduct such an advanced study.” “We weren’t shocked by the results, but I am extremely eager to carry out further research. “I chose to study ecology at UEA as I have a passion for trying to protect and conserve nature. I wanted a better understanding of the global situation and so chose UEA to study ecology and conservation. “The plan after graduation is to do an extended study of viruses in UK bats, very similar to the one I carried out as an undergraduate. There is still a lot more to understand and I am extremely excited to see what else we can find out.” But she says that she doesn’t want her research to turn people against bats. “More than anything, I’m worried that people may suddenly start fearing and persecuting bats, which is the last thing I would want and would be unnecessary. As like all wildlife, if left alone they do not pose any threat.” ‘Metagenomic identification of a new sarbecovirus from horseshoe bats in Europe’ is published on the Research Square pre-print server. Read the full story, including a Q&A with all you need to know.
COVID expert: Prof Lawrence Young, UK
Professor Lawrence Young of the University of Warwick is one of the go-to experts in the UK on COVID-19. A Professor of Molecular Oncology at Warwick Medical School, he can comment on many aspects of the pandemic -- from the nature of the virus itself and its effects in patients, to its impacts on hospitals and wider society. He regularly features on TV, radio, and newspapers in the UK and worldwide, including: If you would like to book an interview with Prof. Young, contact press@warwick.ac.uk or L.Walton.1@warwick.ac.uk
Earlier this week, President Joe Biden proclaimed that April 11 thru 17 would be Black Maternal Health Week in America. In Georgia, the state has consistently been ranked as one of the most dangerous places in this country to be a new mother. Approximately 26 Georgia women die from pregnancy complications for every 100,000 live births, compared to the national average of about 17 women. But even more devastating is the fact that about 60% of the state’s maternal deaths between 2012 and 2016 were found to be preventable, according to the Georgia Department of Public Health. And the mortality rates are much more tragic for Black women in Georgia. African American women are almost three times more likely to die from a pregnancy-related cause than white women in Georgia. Black mothers in rural areas of Georgia are at an even higher risk. “Maternal and infant mortality are really significant indicators of the quality of health in any area, so my colleagues around Georgia really felt challenged to do something that we hadn’t done in a long time in our state, which was to get the data,” says Dr. Chad Ray. “Because you can’t really fix something unless you know who and why. And then you assemble the stakeholders to formulate a plan to make a dent and to move the needle on something that is just so important.” This is an important topic that impacts mothers in Georgia and across the entire United States. And if you are a journalist looking to cover this topic – then let us help. Dr. Chad Ray is the Interim Section Chief of the Department of Obstetrics and Gynecology at the Augusta University Medical Center. He is an expert in the areas of maternal mortality & global women's health initiatives. Dr. Ray is available to speak with media about Black Maternal Health Week - simply click on his icon now to arrange an interview today.
